GlassScriptPhysician profile
Valery Uhl
NPI 1760608897
$33,653.35
in general payments reported to CMS, 2019-2025
64 companies · $17.58 in 2025
The $17.58 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,181 · 2020: $9,529 · 2021: $5,916 · 2022: $866 · 2023: $14K · 2024: $1,355 · 2025: $17.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,750 · Travel and Lodging: $4,192 · Food and Beverage: $2,830 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,300 · Education: $88.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,750.00 |
| Travel and Lodging | $4,192.35 |
| Food and Beverage | $2,829.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,300.00 |
| Education | $88.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $15,351.49 | 2021-2023 | Iort, Intrabeam, Intrabeam 600 |
| Carl Zeiss Meditec, INC. | $12,166.48 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $456.69 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $455.92 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $387.03 | 2019-2024 | Alunbrig, Ninlaro, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $325.44 | 2019-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $304.39 | 2020-2024 | Enhertu, Calquence, Imfinzi |
| Amgen INC. | $276.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $255.77 | 2019-2024 | |
| Daiichi Sankyo INC. | $225.66 | 2019-2024 | Enhertu |
| Janssen Biotech, INC. | $210.41 | 2019-2024 | Erleada, Darzalex, Imbruvica |
| Emd Serono, INC. | $173.06 | 2019-2024 | |
| Eisai INC. | $169.47 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $162.78 | 2021-2023 | Libtayo |
| Lilly USA, LLC | $144.85 | 2023-2024 | Jaypirca, Verzenio |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valery Uhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.